



November 12, 2025

To,
Asst. General Manager,
Dept. of Corporate Services.
Bombay Stock Exchange Limited,
14th Floor, P.J. Towers, Dalal Street,
Fort, Mumbai: 400 001, Maharashtra, Mumbai.

Respected Sir,

Sub: Outcome of the Board Meeting held on Wednesday, November 12, 2025.

With reference to the above captioned subject, we wish to intimate your esteemed exchange that as decided in the Meeting of the Board of Directors of the Company held today, i.e. on November 12, 2025, for which intimation was already given to you, the Board of Directors has:

1. Taken on record the Unaudited (Provisional) Financial Results of the Company for the quarter ended September 30, 2025, along with the Limited Review Report;
2. Taken note of demise of Mr. Benegal Parameshwara Udpa (DIN: 08563819), Non-Executive, Independent Director of the Company;
3. Proposed to appoint Mr. K. Raghupathi Bhat as a Non-Executive Director of the Company with effect from procurement of valid Director Identification Number (DIN) subject to approval of relevant authorities.

In connection with Point No. 1, please find enclosed the copy of Un-audited Standalone financial Results of the Company for the quarter ended September 30, 2025 along with Limited Review Report by the Statutory Auditors of the Company as "*Annexure-I*".

The meeting of Board of Directors held today at 12.00 pm (IST) and concluded at 12.30 pm (IST).

The above intimation is given to you for your record.

Thanking You,
Yours faithfully,
For Adeshwar Meditex Limited

Krishnojirao Nagaraja Rao
Director
DIN: 07684308

Encl: as above



Factory : 17/18, Dewan & Sons Udyog Nagar, Palghar (West) 401 404. (M.S.) India.

Tel. : +91 - 2525 - 252058 / 250687 • **Cell No.** : +91 - 9325015511.

Customer Care No. : +91 - 9594062173

Adeshwar Meditex Limited
CIN : L52390MH2007PLC169544

Statement Of Unaudited Financial Results For The Half Year And Year Ended 30th September 2025

(Rs. in Lakhs)				
Particulars	Half Year Ended 30.09.2025 (Unaudited)	Half Year Ended 30.09.2024 (Unaudited)	Year Ended 31.03.2025 (Audited)	Year Ended 31.03.2024 (Audited)
Revenue From Operations	3,005.78	4,089.59	8,371.31	7,985.02
Other Income	5.21	21.02	25.86	13.28
Total Income	3,010.99	4,110.61	8,397.17	7,998.30
<u>Expenses:</u>				
Cost of Materials Consumed	2,315.58	3,561.58	7,358.22	7,274.99
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	206.29	119.65	83.59	(294.45)
Employee Benefit Expense	147.25	78.19	219.61	176.48
Finance Costs	36.25	70.71	133.39	192.33
Depreciation and Amortisation Cost	21.30	24.70	49.94	60.13
Other Expenses	182.72	130.37	273.08	310.28
Total Expenses	2,909.39	3,985.20	8,117.83	7,719.76
Profit Before Prior Period Items ,Exceptional and Extraordinary Items and Tax	101.60	125.41	279.34	278.54
Tax Expense:				
(1) Current Tax	28.50	35.00	82.50	80.00
(2) Deferred Tax	-	-	9.73	2.27
Profit From The Period	73.10	90.41	206.57	200.80
Earning Per Equity Share:				
Face Value Per Equity Shares Rs.10/- Fully Paid up.				
(1) Basic	0.51	0.63	1.43	1.39
(2) Diluted	0.51	0.63	1.43	1.39

For & On Behalf of the Board
For Adeshwar Meditex Limited


Ashalata Raut
Managing Director
DIN : 02608730
Date : 12-11-2025



Adeshwar Meditex Limited
CIN : L52390MH2007PLC169544
Unaudited Statement of assets and Liabilities As At 30th Sep, 2025

(Rs. in Lakhs)

Particulars	30th September 2025	30th September 2024	31st March 2025 (Audited)	31st March 2024 (Audited)
I. EQUITY AND LIABILITIES				
(1) Shareholder's Funds				
(a) Share Capital	1,443.14	1,443.14	1,443.14	1,443.14
(b) Surplus	2,325.76	2,138.22	2,252.80	2,047.81
(2) Non-current liabilities				
(a) Long-Term Borrowings	319.75	189.59	194.05	105.89
(b) Other Long Term Liabilities	-	-	-	-
(c) Long Term Provision	42.94	37.16	42.94	33.54
(3) Current liabilities				
(a) Short-Term Borrowings	290.39	1,017.91	1,051.53	1,282.91
(b) Trade Payables	-	-	-	-
(A) Total Outstanding Dues of Micro Enterprises and Small Enterprises; and	-	-	-	-
(B) Total Outstanding Dues of Creditors Other Than Micro Enterprises and Small Enterprises	1,803.80	1,608.37	2,121.40	1,452.59
(c) Other Current Liabilities	9.94	12.42	93.84	20.61
(d) Short-Term Provisions	34.74	9.78	20.35	17.13
Total	6,270.47	6,456.60	7,220.05	6,403.63
II.Assets				
(1) Non-Current Assets				
(a) Property, Plant and Equipment and Intangible Assets				
(i) Property, Plant and Equipment				
(iii) Capital work-in-progress	281.12	320.13	295.48	352.92
(b) Non-Current Investments	-	-	-	9.80
(c) Long Term Loans and Advances	160.13	206.84	168.87	103.28
(d) Deferred Tax Asset (Net)	23.27	13.54	23.27	13.54
(e) Other Non Current Assets	133.02	147.08	127.00	211.62
(2) Current Assets				
(a) Inventories	2,183.93	2,480.90	2,582.39	2,652.81
(b) Trade Receivables	3,248.21	2,584.71	3,498.29	2,527.16
(c) Cash and Cash Equivalents	4.72	329.71	203.86	115.77
(d) Short-Term Loans and Advances	234.32	356.00	301.79	398.92
(e) Other Current Assets	1.73	17.69	19.09	17.82
Total	6,270.47	6,456.60	7,220.05	6,403.63

For & On Behalf of the Board
For Adeshwar Meditex Limited


Ashalata Raut
Managing Director
DIN : 02608730
Date : 12-11-2025




Adeshwar Meditex Limited		
CIN : L52390MH2007PLC169544		
Unaudited Consolidated Cash Flow Statement For The Period Ended Sep 30, 2025		
(Rs. in Lakhs)		
Particulars	For the Period ended September 30, 2025	For the Year ended March 31, 2025
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net profit before tax and extraordinary items	101.60	279.34
Adjustments for:		
Depreciation and amortization expense	21.30	49.94
(Profit) / Loss on sale of fixed assets	-	0.64
Interest Paid	35.80	116.16
Interest Received	(4.81)	(10.72)
Gain on sale of Mutual Fund	-	(12.37)
Loang Term Provision For Gratuity	-	9.40
Share Issue Expenses	3.35	6.73
Operating profit / (loss) before working capital changes	157.25	439.12
Changes in working capital:		
Increase / (Decrease) in Inventories	398.46	70.42
Increase / (Decrease) in Payables	(317.59)	668.80
Increase / (Decrease) in Receivables	250.08	(971.13)
Increase / (Decrease) in deferred tax liabilities	-	-
Increase / (Decrease) in Short Term Provision	14.39	3.22
(Increase) / Decrease in Other current Liabilities	(83.90)	73.23
(Increase) / Decrease in Other Current Assets	17.36	(1.27)
(Increase) / Decrease in Other Non-Current Assets	(6.02)	84.62
Increase / (Decrease) in Short Term Loans and Advances	67.46	97.13
CASH FLOW FROM / (USED IN) OPERATING ACTIVITIES	340.23	25.02
Less: Taxes paid	497.48	464.14
Less: Taxes for Earlier Years	28.50	82.50
NET CASH FLOW FROM / (USED IN) OPERATING ACTIVITIES	0.15	1.59
	468.83	380.06
B. CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of tangible / intangible assets	(6.94)	(14.93)
Sale of tangible / intangible assets	-	22.42
(Increase) / Decrease in long term loan and advances	8.74	36.52
(Increase) / Decrease in non-current investments	-	9.80
(Profit)/Loss on redemption of investments (Mutual Fund)	-	12.37
Dividend/ bank interest received	4.81	10.72
Loss on sale of Fixed Assets	-	(0.64)
NET CASH FLOW FROM / (USED IN) INVESTING ACTIVITIES	6.61	76.27
C. CASH FLOW FROM FINANCING ACTIVITIES		
Interest expenses	(35.80)	(116.16)
Changes in Long Term Borrowing	125.70	88.16
Proceeds from Share Capital	-	-
Changes in Short Term Borrowing	(761.14)	(231.38)
Share Issue Expenses	(3.35)	(6.73)
Changes in Other Long Term Liabilities	-	-
Dividend paid	-	-
NET CASH FLOW FROM / (USED IN) FINANCING ACTIVITIES	(674.59)	(266.11)
NET INCREASE / (DECREASE) IN CASH & CASH EQUIVALENTS (A+B+C)	(199.15)	190.21
Cash and Cash equivalents at beginning period (Refer Note 18)	203.86	13.65
Cash and Cash equivalents at end of period (Refer Note 18)	4.72	203.86
D. Cash and Cash equivalents comprise of		
Cash on hand	3.34	1.95
Balances with banks		
In current accounts	1.37	201.91
Total	4.72	203.86
This Cash Flow Statement has been prepared as per "Indirect Method" as prescribed by Accounting Standard -3 (revised) "Cash Flow Statements"		



Notes:

1. The unaudited financial results were reviewed by the Audit Committee and taken on record by the Board of directors at their meeting held on 12th November, 2025.
2. As required under Regulation 33 of the SEBI (LODR) Regulations, 2015, the Statutory Auditors have issued Limited Review Reports on the aforesaid unaudited financial results for the half year ended 30th September, 2025, which were also approved by the Audit Committee and Board at their meeting held on 12th November, 2025.
3. The Earning per share (EPS) has been computed in accordance with the Accounting Standard on Earnings per share (AS 20).
4. The company is engaged in the Manufacturer and Trader of Medical Dressings, Bandages, Face Mask and PPE kits.
5. As per MCA Notification dated 16* February 2015, companies whose shares are listed on SME exchange as referred to in Chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009 are exempted from the compulsory requirement of adoption of IND-AS. As the company is covered under the exempted category, it has not adopted IND-AS for preparation of financial results.
6. Figures of Previous year/Period have been regrouped/recast wherever necessary, in order to make comparable.



Independent Auditor's Limited Review Report on the Unaudited Financial Results for the Half Year ended on 30th Sep, 2025 of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To
The Board of Directors
ADESHWAR MEDITEX LIMITED.
Mumbai


Dear Sir,

Re: Limited Review Report of the Unaudited Financial Results for the Half Year ended on 30th Sep, 2025.

We have reviewed the accompanying Statement of Unaudited Financial Results of Adeshwar Meditex Limited ("the Company") for the Half Year ended on 30th Sep, 2025 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 ('the Regulation') as amended.

The Preparation of this Statement is the responsibility of the Company's Management and approved by the Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25 -Interim Financial Reporting ' (AS 25)". prescribed under Section 133 of the Companies Act. 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.


We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become



aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of Unaudited Financial Results prepared in accordance with applicable Accounting Standards specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For RAJESH H GUPTA & CO.
Chartered Accountants
ICAI F.R.No. 133884W



CA Rajesh Kumar Gupta
Partner
M.No.: 147453
Udin NO 25147453BMKMRZ5647
Date:- 12-11-2025
Place:- Mumbai

